Carbapenems in Pediatrics
Authors:
- Sumati NambiarSNSumati Nambiar
- Yuliya YasinskayaYYYuliya Yasinskaya
- Barbara A. JantauschBJBarbara A. Jantausch
- 1 October 2003
- journal article
- review article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 25 (5) , 593-599
Abstract
Antimicrobial resistance is increasing among bacterial pathogens. In particular, organisms producing extended spectrum beta-lactamase enzymes (ESBLs) and AmpC chromosomal beta-lactamase enzymes are resistant to third generation cephalosporins and pose a formidable challenge in the management of seriously ill patients. Carbapenems are a class of broad-spectrum antibiotics with stability against ESBL and AmpC chromosomal beta-lactamases. They are well tolerated by patients. This review will examine the pharmacokinetic and pharmacodynamic properties of two carbapenems imipenem and meropenem and discuss their clinical use in children. References are limited to the English language and extend back to 1980. Sources include computerized databases such as MEDLINE searched using PubMed, and bibliographies of recent articles and books. Approximately 50% of the articles initially reviewed are included in the bibliography. Carbapenems are efficacious in the treatment of a variety of bacterial infections including meningitis, pneumonia, intraabdominal infections, bone, joint and urinary tract infections. The broad spectrum activity and comparatively low toxicity of carbapenems make them valuable therapeutic agents in the treatment of seriously ill patients with bacterial infections. These agents should be used judiciously in order to minimize the risk for development of carbapenem-resistant pathogens.Keywords
This publication has 43 references indexed in Scilit:
- Variations in the Prevalence of Strains Expressing an Extended‐Spectrum β‐Lactamase Phenotype and Characterization of Isolates from Europe, the Americas, and the Western Pacific RegionClinical Infectious Diseases, 2001
- Increasing threat of Gram-negative bacteriaCritical Care Medicine, 2001
- Comparative Pharmacokinetics of the CarbapenemsClinical Pharmacokinetics, 2000
- Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs)Clinical Microbiology and Infection, 2000
- Carbapenems in Serious InfectionsDrug Safety, 2000
- Carbapenems in clinical practice: a guide to their use in serious infectionInternational Journal of Antimicrobial Agents, 1999
- Pharmacokinetic determinants of carbapenem therapy in neonates and childrenThe Pediatric Infectious Disease Journal, 1996
- Interactions in vitro between agents used to treat melioidosisJournal of Antimicrobial Chemotherapy, 1989
- Carbapenems, a new class of beta-lactam antibioticsThe American Journal of Medicine, 1985
- Metabolism of Thienamycin and Related Carbapenem Antibiotics by the Renal Dipeptidase, Dehydropeptidase-IAntimicrobial Agents and Chemotherapy, 1982